Frederick O. Cope, CEOMy inspiration began early and came from two powerful influences.
The first was my family. My father was a physician and surgeon, and my mother was a nurse. Beginning at the age of five, I accompanied my father on house calls and hospital visits. Watching him care for patients, and seeing how the medicines he prescribed could help restore their health, left a lasting impression on me.
The second influence was the emergence of television in the 1950s. I was captivated by biographical films about pioneers such as Louis Pasteur, Marie Curie, Edward Jenner and other scientific innovators. Their stories sparked my imagination and fueled my fascination with discovery and healing. Inspired by what I saw, I even conducted my own experiments in our basement, though not always with successful results.
These experiences shaped my sense of purpose from a very young age. I knew I wanted to pursue a path that combined science, innovation and medicine. I was eager to develop the skills that would one day give me the opportunity to design medicines and advance new approaches that could improve patients' lives.
Protecting the Integrity of Clinical Trials
The realm of clinical trials, as far back as I can remember, has suffered from a failure to respect the impact and rationale of clinical trial protocols on study outcomes. Today, especially, clinical trial failure is often the result of excessive political and extracurricular influence.
In my view, all trials, particularly Phase 3 trials, are built around a focus on success derived from sound science, the statistics supporting that science and the clinical efficacy that emerges from the marriage of these factors. Together, they define a study design centered on patient benefit.
When studies allow deviations or intra-study medical practices to irrationally or politically stray from that objectively defined structure, the outcome of the trial is put at risk. I believe such conduct can produce an untrue answer regarding the utility of a drug. In other words, a bad drug can appear good or a good drug can appear bad. Neither result accomplishes anything; both do harm.
I believe improved clinical trial vigilance and greater respect for the rigor of trial design are needed to ensure the reliability of clinical trial outcomes.
Great Science Starts with Great Teams
Building a highly integrated team with deep expertise across medicine, science, drug law and operations is, in my view, the best approach to this challenge. The importance of such a team cannot be overstated.
-
To use AI effectively in drug development, one must realize that AI is not the tool. It is an amorphous set of 1s and 0s. You are, and must be, the tool.
Success begins with operational integration at the idea stage. Early and critical assessment is essential. However, such an approach can only succeed in an environment where ideas and concerns can be freely expressed, and where serious issues are not overshadowed by extracurricular influences.
While this may not always reflect the real world, striving toward that ideal remains necessary if we are to successfully balance scientific innovation, patient safety and evolving regulatory requirements.
Using AI to Find Better Answers
I say this without any intention of patronizing the current trend, but AI can be a remarkable aid throughout the drug development process. We have used it, and continue to use it, extensively.
To use AI effectively, I believe it is important to recognize that AI is not the tool. It is an amorphous collection of 1s and 0s. In my view, the team is the tool. AI only works when a team is skilled enough to develop sophisticated interrogative constructs that force it to behave objectively.
We have had great success with our approaches to both preclinical and clinical AI assessments. These methods have helped us avoid safety issues, improve drug administration strategies, establish dosing parameters, design efficacy standards and manage changes in trial design. The result is significantly reduced development costs and timelines.
Most importantly, patients are safer, and clinical trials are better designed to deliver a true answer.
Skills Matter, Mindset Matters More
Regardless of whether someone is a PhD, MD or another professional involved in drug development, I believe understanding clinical trial design is critical. Equally important is understanding how to integrate diverse skills into the drug development process.
In my experience, medical practice, statistics, chemistry, disease idiosyncrasies, disease natural history and regulatory affairs are all essential areas of expertise. Creating an environment where critical thinking and open discussion can flourish will lead to meaningful outcomes with a lower probability of error.
Above all, I believe a patient-centered mindset should drive the team environment. That is the outcome we are all working toward. When patients win, everyone wins.
Evaluating Clinical Trial and Drug Development Services In Modern Oncology
Drug development in oncology demands far more than scientific discovery. Pharmaceutical and biotechnology companies must navigate an intricate path that stretches from early molecular insight to clinical validation, regulatory approval and eventual therapeutic adoption. Failures often occur not because the science lacks promise but because the development process cannot translate laboratory insight into clinically meaningful results. Executives responsible for selecting clinical trial and drug development partners therefore look for organizations that combine scientific depth, translational experience and an understanding of how therapies behave within complex biological systems.
The modern oncology pipeline reflects growing recognition that tumors interact continuously with immune cells and surrounding tissue. Therapies designed in isolation from these dynamics rarely achieve durable clinical outcomes. Development partners must therefore demonstrate the ability to interpret tumor biology at a functional level, translating cellular mechanisms into therapeutic strategies that can be tested safely in human studies. Scientific programs that address immune interactions, tumor signaling and diagnostic visibility increasingly guide the next generation of oncology development efforts.
Another dimension of successful development lies in the ability to adapt molecules and technologies across diagnostic and therapeutic contexts. A compound designed for imaging may reveal properties that support treatment. A delivery mechanism developed for one indication may later enable a different therapeutic pathway. Drug development services that recognize such opportunities can extend the value of early discoveries while controlling cost and time. The process demands scientific judgment as well as experience across preclinical research, clinical trial design and regulatory navigation.
Leadership experience also influences the reliability of a development partner. Clinical trial programs often span many years, and each stage introduces new scientific, financial and regulatory risks. Organizations guided by teams that have participated in approved therapies tend to anticipate these challenges more effectively. Familiarity with regulatory expectations, trial design pitfalls and translational barriers helps reduce delays that frequently derail promising therapies before they reach patients.
Scientific flexibility also matters when addressing diseases that receive limited attention from large pharmaceutical organizations. Rare cancers or complex immune conditions often require unconventional approaches that combine targeted therapies, immune modulation or novel delivery technologies. Development partners capable of exploring multiple scientific pathways while maintaining clinical discipline offer particular value to organizations pursuing treatments in these difficult areas.
Physis International reflects this kind of translational development environment. The company was formed by scientists and clinical researchers who previously collaborated on a pharmaceutical program that achieved FDA approval for detecting the spread of several cancers, including breast cancer and melanoma. Their subsequent work builds on that molecular platform by exploring therapeutic uses of the underlying compound and modifying it to interact differently with immune cells surrounding tumors.
The company’s research explores methods that encourage immune cells near tumors to shift behavior so that they support anti-tumor activity rather than suppress it. Variations of the molecule can remove macrophages that protect tumors, allowing new immune cells to stimulate a targeted response. Other programs introduce fluorescent markers that allow surgeons to visualize metastatic tissue directly under light. Another approach activates the therapy only when exposed to light near the tumor site, limiting unintended effects in organs such as the liver. Physis International is also investigating gene-based strategies that make tumors more responsive to treatment and vaccine concepts designed to stimulate anti-tumor immunity, positioning it as a compelling partner for oncology development programs.
...Read more
